Summary The present phase 11 trial was undertaken to assess the efficacy and toxicity of a combination of paclitaxel and carboplatin as firstline chemotherapy in patients with metastatic transitional cell carcinoma of the urothelium. Twenty patients (age range 50-79 years; inclusion criteria: WHO performance status 0-2. no previous cytotoxic treatment) with metastatic transitional cell carcinoma of the urothelium were recruited and received cytotoxic treatment with paclitaxel at a dosage of 175 mg m-2 administered over a 3-h infusion and carboplatin given at an AUC of 5 mg ml-min (according to creatinine clearance) administered every 21 days. A total of 65% of patients achieved remissions (CR+PR), with CR occurring in 40% of patients. A further 15% of patients experienced stable disease. Remissions occurred after 2.4 ± 0.8 (mean ± standard deviation; range two to four) treatment cycles. The mean duration of responses (CR+PR) was 8.5 ± 5.5 months. After a mean observation period of 11.4 ± 4.8 months, 16 patients (80%) are alive. Toxicity included alopecia of WHO grade 3 in all patients, leucopenia of WHO grades 1 and 2 in ten patients, grade 3 in eight and grade 4 in two patients and, finally, severe thrombocytopenia grade 3 in only three patients. Non-haematological toxicity consisted of polyneuropathy of WHO grade 1 in 13 patients and grade 2 in five patients. We thus conclude that a combination of paclitaxel and carboplatin at the given dosage and schedule constitutes an active, well-tolerated first-line cytotoxic treatment for patients with metastatic urothelial cancer.
Treatment of metastatic cancer of transitional cells of the urothelium by cytotoxic chemotherapy has led to marked improvement in the prognosis of patients suffering from this disease. Before the development of effectixe chemotherapy. survival of patients with metastatic urothelial cancer rarely exceeded 3-6 months. In contrast. combination chemotherapy has significantly improved survival rates bv inducing, remissions in over 70%7 of patients (Harker et al. 1985 : Sternberg et al. 1985 : Logothetis et al. 1990a ). Although a series of combinations of cytotoxic drucs has been studied. treatment with methotrexate. xinblastine. doxorubicin and cyclophosphamide (cisplatin) (M-VAC) has become therapy of choice because of its favourable efficacy (Sternberg et al. 1988 : Loehrer et al. 1992 . exver since its development at Memorial Sloan-Ketterinc Cancer Center in 1983 (Sternberg et al. 1985) .
Although cisplatin is thought to be the most active acent of this combination. M-VAC was found to be superior over single-agent therapy with this drug (Loehrer et al. 1992) . Howxexver. the administration of M-VAC can produce a series of side-effects. includincg mvelosuppression. sepsis. mucositis. peripheral neuropathy and nephrotoxicity (Loehrer et al. 1992 ). Amona others. it is mainlv nephrotoxicitv that prexents the inclusion of many. in particular elderly. patients uwith advanced urothelial cancer who often haxe decreased renal function under this treatment protocol. Several modifications of the standard M-VAC regimen hax e been proposed. including the substitution of epirubicin for doxorubicin to reduce cardiotoxicityr or of carboplatin for cisplatin (Petrioli et al. 1996) to reduce nephrotoxicity. Moreover. attempts haxe been made to replace cisplatin by aallium nitrate under the addition of X inblastine and ifosfamide (Einhomn et al. 1994) .
The adxent of newer cvtotoxic drugs has changed the scenanro in advanced urothelial cancer. as significant single-drug actixitV has been reported not only for carboplatin (Mottet-Auselo et al. 1995) but also for agents such as paclitaxel (Roth et al. 1994) as well as gemcitabine (Pollera et al. 1994 : Stadler et al. 1997 : xon der Maase et al. 1997 . Confronted wxith the limitations and toxicities of M-VAC chemotherapy outhned aboxe and based upon earlier studies that hax-e demonstrated impressi-e single-agent efficacy of paclitaxel leading to an objectixve response rate of 42%l (Roth et al. 1994) Paclitaxel (175mg m-body surface) was gixen by a 3-h continuous infusion subsequently followed by carboplatin given at an AUC of 5 mg ml-' mmn according to creatinine clearance on day 1 of a , 1 -day cycle. This combination has been shown to be safe in previous inxestigations (Spencer et al. 1994 ).
Supportive therapy Antianaphylactic drug therapy consisting of cimetidine. diphenhydramine and dexamethasone was given before taxol treatment. and standard antiemetic medication was administered 
RESULTS

Response to treatment
After a mean follow-up of 11.4 ± 4.8 months. 8 (40%) out of 20 patients have achieved complete remission (CR) and five (25%) partial remission (PR), resulting in an overall response rate (CR + PR) of 65%. Moreover, three patients (15%) have experienced stable disease (SD). The remaining four patients (20%) had progressive disease despite the treatment. The mean number of treatments needed to achieve responses was 2.4 ± 0.8 (range two to four). No difference in the number of ratment cycles needed to achieve responses was found between patients with CR (2.4 ± 0.7) and PR (2.4 ± 0.8). The mean number of treatment cycles administered was 5.8 ± 0.7 (range 4-6) in patients with CR and 4.4 ± 0.9 (range 3-6) in patients with PR. The duration of responses was 8.5 ± 5.5 (range 1.1-14.9) months in patients with achieved CR and 7.1 ± 4.2 (range 2.3-11.7) months in patients with PR. Figure 1 shows a Kaplan-Meier plot for recurrence or progression of disease. In a detailed analysis, no significant difference in overall survival was found between patients < 69 (9 of 11 patients alive) and > 70 years (seven of nine patients alive; P > 0.05) and, interestingly, between patients with various responses to treatment (CR: seven of eight patients alive; PR: four of five patients alive; P>0.05).
Response according to lation of etasta Table 2 shows the rate of responses in dependence upon the location of metastases. It is noteworthy that 10 out of 12 patients with exclusively lymph node metastases achieved response (CR + PR).
Treatmet-associated toxicity
Treatment-associated toxicity including polyneuropathy, leucopenia and thrombopenia was generally low. The only exception was alopecia grade 3 (WHO), which was experienced in all 20 patients. A detailed description of toxicities is given in Table 3 .
Low teataent-associated toxicity was also observed in nine patients >70 years who were also analysed separately (Table 3) and Duration of remissions and survival After a mean observation period of 11.4 ± 4.8 (range 4-17) months. 16 out of 20 patients (80%) are alive. whereas the remaining four patients have died as a result of progressive carcinoma. Thus, 82.5% of patients have experienced an overall survival of 9.1 months (Figure 1 ). Seven patients have remained in CR for a mean duration of 9.1 (range 1.3-14.9) months, including one patient with liver metastases (Table 2 ) whose duration of CR is 7.5 months at the time of preparation of the manuscript.
DISCUSSION
Cytotoxic treatment consisting of a combination of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) has proved to represent effective tatment for metastatic urothelial cancer by primarily leading to responses in 72% (36% CR) of 121 assessable patients (Stemnberg et al, 1989) . In further trials, responses were observed in 42-57% (CR 13-19%) of patients (Chong et al, 1987; Hillcoat et al, 1989; Tannock et al, 1989; Igawa et al, 1990; Boutan-Laroze et al, 1991 ). An intergroup phase HI study resulted in a response rate of 39% (CR 13%) of patients whose median survival was 12.5 months (Loehrer et al. 1992 ). This latter trial also addressed the question of the importance of single-agent therapy with cisplatin (70 mg m-body surface), which has been discussed to be mainly responsible for the good efficacy of the entire regimen. However, responses achieved in the cisplatin arm were only 12% (CR 3%; Loehrer et al. 1992) . Further attempts to increase the efficacy of M-VAC by an increase in dose intensity through the inclusion of colony-stimulating factors were unsuccessful (Logothetis et al, 1990b; Seidman et al. 1993) . Although remaining the tratment of choice in patients with advanced urothelial cancer, M-VAC is hampered by. at times, high toxicity (Stemberg et al, 1989; Logothetis et al, 1990b; Loehrer et al, 1992) . Thus, with the introduction of newer cytostatic drugs, including gemcitabine and paclitaxel, the possibility of increasing efficacy with low concomitant reatmnt-associated toxicity had to be re-examined (Pollera et al, 1994; Roth et al, 1994) . Setting out from the concept that the antimicrotubular agent paclitaxel, which had proved to be effective in a series of tumours in vivo (Ozols, 1995) and against human bladder tumour cell lines in vitro (Rangel et al, 1994) (1998) 78(3), 370-374 (Roth et al. 1994) . Responses reached 42% (CR 27%. PR 15%l). and cvtotoxic treatment w-as relativelv well tolerated: however. because of the high dose of paclitaxel. the protocol had to include granulocy-te colony-stimulating factor. In an attempt to further ameliorate these findings. while trying to keep toxicity low in a population of patients w-ith metastatic urothelial cancer. w-hich because of epidemiological reasons often consists of elderly persons with reduced organ function as a result of advanced age. we have tested for the efficacy and toxicity of a combination of paclitaxel in a louwer dose under the addition of carboplatin. w-hich has also been shown to exert sinale-aaent activity in advanced urothelial cancer (Mottet-Auselo et al. 1995 (Roth et al. 1994) .
responses in the present study w-ere higher (65%c vs 42%). w-ith a higher frequency of CRs (40%c vs. 27%c) in populations of patients similar in number (20 vs 26). thus suggesting that the results obtained in the present trial were most probably not related to the administration of paclitaxel alone. M-VAC polychemotherapy has been shown to produce frequent treatment-associated side-effects.
including myelotoxicity in 76%7c. nephrotoxicity (grades 3 and 4) in 7%7. mucositis in 17% and polneuropathv in 5%s of 126 patients (Loehrer et al. 1992 ). In contrast. in the present trial. mvelotoxicitv w-as infrequent and severe polyneuropathv of grades 3 or 4 was not encountered. It is important to stress that patients over the age of 70 -ears did not experience significantly increased toxicity compared w-ith younger patients. thus making the protocol also applicable for an older patient population with advanced urothelial cancer. We thus conclude that a combination of paclitaxel and carboplatin constitutes effective treatment of advanced urothelial cancer and is well tolerated.
